Loading
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Latest quote
$1.315
−$0.04 · -2.95%
After-hours
$1.3131
−$0.0019 · -0.14%
Sep 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Day range
Current $1.315
52-week range
Current $1.315
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
28
Expensive
Sentiment
67
Bullish
Risk
82
Extreme Risk
Momentum
66
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Day range
Current $1.315
52-week range
Current $1.315
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 424K USD | — | 357K USD | — | — |
| Gross profit | −424K USD | — | −357K USD | — | — |
| Research and development | 18.13M USD | 15.75M USD | 16.97M USD | 14.17M USD | 11M USD |
| Selling, general, and administrative | 9.43M USD | 8.93M USD | 10M USD | 5.37M USD | 2.32M USD |
| Operating expenses | 27.13M USD | 24.68M USD | 26.61M USD | 21.24M USD | 13.32M USD |
| Depreciation and amortization | 424K USD | 400K USD | 357K USD | 381K USD | 345K USD |
| Operating income | −27.56M USD | −24.68M USD | −26.97M USD | −21.24M USD | −13.32M USD |
| Net income | −26.61M USD | −23.49M USD | −25.65M USD | −13.89M USD | −12.77M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 19, 2022 | 1:3 | — | — |
Stock split | Jan 6, 2020 | 1:8 | — | — |
Effective Aug 19, 2022
1:3
Effective Jan 6, 2020
1:8
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
